Skip to main content

Table 1 Patients Characteristics

From: A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

  DC
(n = 67)
D
(n = 65)
 
  N (%) N (%) P-value
Age 62 63  
Median (min-max) 39 - 78 39 - 83  
Sex    
Male 64 (95.5) 56 (86.2) P = 0.074
Female 3 (4.5) 9 (13.8)  
Performance status    
0 26 (38.8) 14 (21.5) P = 0.088
1 33 (49.3) 39 (60.0)  
2 8 (11.9) 12 (18.5)  
Histological Type    
Squamous 16 (23.9) 18 (27.7) Adeno Ca vs Non-Adeno Ca
P = 0.380
Adeno Ca 26 (38.8) 31 (47.7)  
Large Cell 2 (3.0) 1 (1.5)  
Mixed 1 (1.5) 1 (1.5)  
Other 22 (32.8) 14 (21.5)  
No. of Organs Involved    
Median (min- max) 2.00 (1 - 8) 2.00 (1 - 5) 1-2 vs > = 3
P = 0.444
    Mann-Whitney U = 2142.500
P = 0.867
Prior therapy    
Paclitaxel 8 (11.9) 7 (10.8) P = 0.109
Response to prior therapy    CR+PR vs SD+PD
P = 0.799
CR 1 (1.5) 1 (1.5)  
PR 7 (10.4) 8 (12.3)  
SD 18 (26.9) 19 (29.2)  
PD 41 (61.2) 37 (56.9)